Elastrography forms the cornerstone of an ultrasound system unveiled by first-time RSNA exhibitor SuperSonic Imagine. The Aixplorer system is dedicated to breast imaging. It differentiates healthy from cancerous tissues by quantifying differences in the elasticity of the tissues. SuperSonic’s ShearWave Elastography technique produces consistent results regardless of the operator’s skill, according to the company.
Elastrography forms the cornerstone of an ultrasound system unveiled by first-time RSNA exhibitor SuperSonic Imagine. The Aixplorer system is dedicated to breast imaging. It differentiates healthy from cancerous tissues by quantifying differences in the elasticity of the tissues. SuperSonic's ShearWave Elastography technique produces consistent results regardless of the operator's skill, according to the company.
Jacques Souquet, Ph.D., former chief technology officer of ATL and later Philips Ultrasound, founded the company in April 2005 in Aix-en-Provence, France, the name source for the firm's new product. The company employs 92 people, including U.S. expatriates and French employees repatriated from the U.S.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.